Sign in Subscribe

MacroGenics to Receive $24.5 Million Milestone Payment from Sanofi Following FDA Approval of TZIELD for Stage 3 Type 1 Diabetes

MacroGenics receives $24.5 million from Sanofi after FDA expands TZIELD approval to children aged 8-17 with newly diagnosed stage 3 Type 1 diabetes.

MacroGenics to Receive $24.5 Million Milestone Payment from Sanofi Following FDA Approval of TZIELD for Stage 3 Type 1 Diabetes
Credit: MacroGenics
Already have an account? Sign in.